Cardio vascular diseases are one of the leading causes of death among people in India. Heart attacks are the most common type of cardio vascular diseases. Apart from that, various other CVDs including peripheral arterial disease, cerebrovascular disease, congenital heart disease, deep vein thrombosis and pulmonary embolism are of major concern. Recent developments in heart failure drugs have considerably expanded and led to the emergence of different treatment options for patients with cardio vascular diseases.
Entresto is a drug adminstered for reducing the risk of cardiovascular deaths. It was approved in 2015 by the Food and Drug Administration (FDA). The drug is a combination of Sacubitril, a neprilysin inhibitor and Valsartan, an angiotensin II receptor blocker. Entresto is meant to act towards enhancing the level of certain types of proteins which are responsible for dilating the blood vessels. Also termed as vasodilation, the process is meant to reduce vascular resistance resulting in reduced cardiac output in chronic heart failure. Sacubitril works as a blood pressure medicine lowering the blood pressure, whereas Valsartan prevents narrowing of blood vessels. The cumulative impact of the medication results in relaxing of blood vessels so that blood can flow more easily, which makes it easier for the heart to pump blood to the body.
In conclusion, Entresto is a prescription medicine. People with certain types of chronic heart diseases benefit from this drug due to low mortality risk.